Spots Global Cancer Trial Database for tuvusertib
Every month we try and update this database with for tuvusertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) | NCT06421935 | Advanced Solid ... | M9466 Tuvusertib | 18 Years - | EMD Serono | |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Endometrial Car... Endometrial Cle... Endometrial End... Endometrial Low... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Low Gra... Platinum-Resist... | BET Bromodomain... Biopsy Biospecimen Col... Computed Tomogr... Electrocardiogr... Magnetic Resona... Tuvusertib X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | NCT05687136 | Advanced Malign... Metastatic Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | NCT05687136 | Advanced Malign... Metastatic Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | NCT05691491 | Advanced Malign... Advanced Micros... Hematopoietic a... Metastatic Mali... Metastatic Micr... Stage III Color... Stage IV Colore... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Temozolomide Tuvusertib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial | NCT05947500 | Clinical Stage ... Clinical Stage ... Locally Advance... Metastatic Merk... Refractory Merk... Unresectable Me... | Avelumab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Positron Emissi... Tuvusertib | 18 Years - | National Cancer Institute (NCI) | |
| M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501) | NCT06421935 | Advanced Solid ... | M9466 Tuvusertib | 18 Years - | EMD Serono | |
| Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | NCT05828082 | Refractory Pros... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Positron Emissi... Tuvusertib Ultrasound Imag... | 18 Years - | National Cancer Institute (NCI) | |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Endometrial Car... Endometrial Cle... Endometrial End... Endometrial Low... Ovarian Clear C... Ovarian Endomet... Ovarian High Gr... Ovarian Low Gra... Platinum-Resist... | BET Bromodomain... Biopsy Biospecimen Col... Computed Tomogr... Electrocardiogr... Magnetic Resona... Tuvusertib X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
